CRISPR Firm Intellia Prices IPO at $16 to $18 Per Share

Apr 27, 2016

|

NEW YORK (GenomeWeb) – Intellia Therapeutics has priced shares for its upcoming initial public offering in the range of $16 to $18, according to an amendment to its preliminary prospectus filed today with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Featured White Papers

High Throughput RT-qPCR for Gene Expression Analysis

Sep

12

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Next-Generation CRISPR: New Tools for Efficient Genome Engineering

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.

Main menu